ИНСУЛИНОРЕЗИСТЕНТНОСТЬ: БЛАГО ИЛИ ЗЛО? МЕХАНИЗМЫ РАЗВИТИЯ И СВЯЗЬ С ВОЗРАСТ-АССОЦИИРОВАННЫМИ ИЗМЕНЕНИЯМИ СОСУДОВ

Обсуждаются механизмы возникновения инсулинорезистентности (ИР), ее роль в развитии основных возраст-ассоциированных изменений сосудов, трансформации старения сосудов в болезнь, вклад ИР в продолжительность жизни. 

1. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature 2008; 451: 716–9.

2. Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science 2002; 296: 1029–31.

3. Wilmoth JR, Deegan LJ, Lundstrom H, et al. Increase of maximum life-span in Sweden. Science 2000; 289:1861–999, 2366–8.

4. Rössner S. Obesity in the elderly – a future matter of concern? Obes Rev 2001; 2: 183–8.

5. Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr 2005; 82: 923–34.

6. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulindependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988–92.

7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–28.

8. Grundy SM. Metabolic syndrome pandemia. Arterioscler Thromb Vasc Biol 2008; 28: 629–32.

9. Hu G, Qiao Q, Tuomilheto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med 2004; 164: 1066–76.

10. Reaven GM. Banting Lecture 1988. The role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.

11. Lechleitner M. Obesity and the metabolic syndrome in the elderly – a mini-review. Gerontology 2008; 54: 253–9.

12. Bjorntorp P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493–6.

13. Albu JB, Kovera AJ, Johnson JA. Fat distribution and health in obesity. Ann NY Acad Sci 2000; 904: 491–501.

14. Tiengo A, Avogaro P, Del Prato S. Pathogenesis and therapy of plurimetabolic syndrome. Nutr Metab Cardiovasc Dis 1996; 6: 187–92.

15. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 74: 761–811.

16. Goodpaster BH, Thaete FL, Simoneau JA, et al. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579–85.

17. Abate N, Garg A, Peshock RM, et al. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 1996; 45: 1684–93.

18. Kuhn TF. The structure of scientific revolutions, 2nd edn. The University of Chicago Press: Chicago; 1962.

19. Snitker S, Tataranni PA, Ravussin E. Respiratory quotient is inversely associated with muscle sympathetic nerve activity. J Clin Endocrinol Metab 1998; 83: 3977–9.

20. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140–2.

21. Tchkonia T, Corkey BE, Kirkland JL. Current views of the fat cell as an endocrine cell: lipotoxicity. Endocrine Updates 2006; 26: 105–18.

22. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171–6.

23. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023–8.

24. Robbins DC, Horton ES, Tulp O, et al. Familial partial lipodystrophy: complications of obesity in the non-obese. Metabolism 1982; 31: 445–52.

25. Wojtanik KM, Edgemon K, Viswanadha S, et al. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan￾type familial partial lipodystrophy mutation. J Lipid Res 2009; 50: 1068–79.

26. Chung S, Lapoint K, Martinez K, et al. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human. Endocrinology 2006; 147 (11): 5340–51.

27. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–7.

28. Jerschow E, Anwar S, Barzilai N, et al. Macrophages accumulation in visceral and subcutaneous adipose tissue correlates with age. J Allergy Clin Immunol 2007; 119 (Suppl 1): S179.

29. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 2347–55.

30. Erridge C, Attina T, Spickett CM, et al. A high-fat meal induces low￾grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286–92. 31. Saito H, Sherwood ER, Varma TK, et al. Effects of aging on mortality, hypothermia, and cytokine induction in mice with endotoxemia or sepsis. Mech Ageing Dev 2003; 124: 1047–58.

31. Oeseburg H, Westenbrink BD, de Boer RA, et al. Can critically short telomeres cause functional exhaustion of progenitor cells in postinfarction heart failure. JACC 2007; 50: 1911–2.

32. Spyridopoulos I, Erben Y, Brummendorf TH, et al. Telomere gap between granulocytes and lymphocytes is a determinant for hematopoetic progenitor cell impairment in patients with previous myocardial infarction. Arterioscler Thromb Vasc Biol 2008; 28: 968–74.

33. Demissie S, Levy D, Benjamin EJ, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell 2006; 5: 325–30.

34. Vasan RS, Demissie S, Kimura M, et al. Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study. Circulation 2008; 117: 1138–44.

35. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 2007; 8: 703–13.

36. Virmani R, Avolio AP, Mergner WJ, et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol 1991; 139: 1119–29.

37. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439–41.

38. Wang M, Zhang J, Jiang LQ, et al. Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension 2007; 50: 219–27.

39. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003; 57: 195–202.

40. Wang M, Lakatta EG. Altered regulation of matrix metalloproteinase-2 in aortic remodeling during aging. Hypertension 2002; 39: 865–73.

41. Sengstock DM, Vaitkevicius PV, Supiano MA. Arterial Stiffness Is Related to Insulin Resistance in Nondiabetic Hypertensive Older Adults; The Journal of Clinical Endocrinology & Metabolism 2005; 90 (5): 2823–7.

42. Tobey TA, Greenfield M, Kraemer F, et al. Relationship between insulin resistance, insulin secretion, VLDL kinetics and plasma triglycerides levels in normotriglyceridemic men. Metabolism 1981; 30: 165–71.

43. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002; 287 (3): 356–9.

44. Hyon K, Earl C, Ford S, et al. Prevalence of the Metabolic Syndrome in Patients With Gout: The Third National Health and Nutrition Examination Survey Arthritis & Rheumatism 2007; 57: 1:109–15.

45. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin￾like signals. Science 2003; 299 (5611): 1346–51.

46. Liang H, Masoro EJ, Nelson JF, et al. Genetic mouse models of extended lifespan. Exp Gerontol 2003; 38: 1353–64.

47. Wijchers PJ, Burbach JP, Smidt MP. In control of biology: of mice, men and Foxes. Biochem J 2006; 397: 233–46.

48. Oh SW, Mukhopadhyay A, Dixit BL, et al. Identification of direct DAF-16 targets controlling longevity, metabolism and diapause by chromatin immunoprecipitation. Nature Genet 2006; 38: 251–7.

49. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340: 925–9.

50. Visser M, Langlois J, Guralnik JM, et al. High body fatness, but not low fat￾free mass, predicts disability in older men and women: the Cardiovascular Health Study. Am J Clin Nutr 1998; 68: 584–90.

51. Kim J, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401–14.

52. Guo W, Pirtskhalava T, Tchkonia T, et al. Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity. Am J Physiol Endocrinol Metab 2007; 292: E1041–51.

53. Motta M, Bennati E, Cardillo E, et al. The metabolic syndrome in the elderly: considerations on the diagnostic criteria of the International Diabetes Federation and some proposed modifications. Arch Gerontol Geriatr 2008; 54: 253–9.

54. Heiat A, Vaccarino V, Krumholz HM. An evidence-based assessment of federal guidelines for overweight and obesity as they apply to elderly persons. Arch Intern Med 2001; 161: 1194–203.

55. Volkert D, Berner YN, Berry E, et al. ESPEN guidelines on enteral nutrition: geriatrics. Clin Nutr 2006; 25: 330–60.

56. Mak HY, Ruvkun G. Intercellular signaling of reproductive development by the C. elegans DAF-9 cytochrome P450. Development 2004; 131: 1777–86 (2004).

57. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170 (14): 1191–201.